Tuesday, December 13, 2011

Researchers say therapy improves stem cell engraftment in umbilical cord blood transplant recipients

http://www.eurekalert.org/pub_releases/2011-12/dci-rst120811.php

"A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by Dana-Farber Cancer Institute scientists indicates."

"Details of the trial (abstract 653), which involved 12 patients who underwent reduced-intensity chemotherapy and then received a transplant of cord blood stem cells treated with the compound FT1050, will be presented at the American Society of Hematology's 2011 annual meeting on Monday, Dec. 12, at 2:45 p.m. PST."

"FT1050-treated blood-forming stem cells are being tested as a possible solution to one of the major shortcomings of transplants involving stem cells from umbilical cord blood: the relatively small number of stem cells infused in such procedures often take longer to engraft – or take root – in patients than do the more numerous stem cells involved in transplants from adult donors. The delay can leave patients susceptible to dangerous infections and other complications."


Another day in the cord blood industry, another positive advancement being made on improving the outcomes using present transplant methods. Great job and kudos to the research team.

No comments:

Post a Comment